– CNBC
Johnson & Johnson’s Arthritis Drug Shows Potential In Crohn’s Disease
Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met all primary and secondary endpoints.
Related Posts
Read Why Mizuho Is Bullish On Kraft Heinz
Mizuho analyst John Baumgartner initiated coverage of Kraft Heinz Co (NASDAQ:KHC) with a Buy rating and a price target of $48, implying…
Insurance Stocks Moving In Thursday’s Intraday Session
According to Benzinga Pro following are the gainers and losers in Insurance industry for today’s Intraday session. Gainers…
CoreCivic Q2 EPS $0.34 Down From $0.46 YoY, Sales $456.70M Miss $460.06M Estimate
CoreCivic (NYSE:CXW) reported quarterly earnings of $0.34 per share. This is a 26.09 percent decrease over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $456.70